Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 1 2

Status

Completed 6Terminated 2Withdrawn 1Active not recruiting 1

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Gynecologic 2Tumor-Agnostic 1Other hematologic neoplasm 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Neoplasms 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Platinum-resistant Ovarian Cancer 1Metastatic Castration-resistant Prostate Cancer 1Hematologic Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Completed × INDUSTRY × afuresertib × Clear all
NCT05383482 2025-11-17

Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1

Laekna Limited

Phase 1/2 Completed
22 enrolled
GastrointestinalGynecologic

Uterine Cervical Neoplasms, Esophageal Neoplasms, Endometrial Neoplasms

NCT04374630 2025-09-10

PROFECTA-II

Laekna Limited

Phase 2 Completed
150 enrolled
Gynecologic

Platinum-resistant Ovarian Cancer

NCT04060394 2024-10-10

Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC

Laekna Limited

Phase 1/2 Completed
49 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT05390710 2024-10-10

PhI to Solid Tumors and PhII to Locally Advanced or mTNBC

Laekna Limited

Phase 1 Completed
21 enrolled
Breast

Triple Negative Breast Neoplasms

NCT01531894 2019-07-09

Continuation Study of the Oral AKT Inhibitor GSK2110183

Novartis

Phase 2 Completed
11 enrolled 8 charts
Other hematologic neoplasm

Neoplasms, Hematologic Neoplasms

NCT02240212 2017-04-11

Study of Afuresertib Combined With Paclitaxel in Gastric Cancer

Novartis

Phase 1 Completed
29 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡